SILODOSIN is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Pd-rx Pharmaceuticals, Inc.. The primary component is Silodosin.
| Product ID | 72789-090_a8c61488-4220-dfcb-e053-2a95a90a98a4 |
| NDC | 72789-090 |
| Product Type | Human Prescription Drug |
| Proprietary Name | SILODOSIN |
| Generic Name | Silodosin |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-12-03 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA210687 |
| Labeler Name | PD-Rx Pharmaceuticals, Inc. |
| Substance Name | SILODOSIN |
| Active Ingredient Strength | 8 mg/1 |
| Pharm Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2020-06-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0781-2623 | Silodosin | Silodosin |
| 0781-2624 | Silodosin | Silodosin |
| 27241-144 | Silodosin | Silodosin |
| 27241-145 | Silodosin | Silodosin |
| 31722-635 | Silodosin | Silodosin |
| 31722-636 | Silodosin | Silodosin |
| 33342-384 | Silodosin | Silodosin |
| 33342-385 | Silodosin | Silodosin |
| 42291-777 | Silodosin | Silodosin |
| 42291-778 | Silodosin | Silodosin |
| 46708-405 | Silodosin | Silodosin |
| 46708-406 | Silodosin | Silodosin |
| 59651-095 | SILODOSIN | SILODOSIN |
| 59651-096 | SILODOSIN | SILODOSIN |
| 68180-740 | Silodosin | Silodosin |
| 68180-741 | Silodosin | Silodosin |
| 69238-1421 | Silodosin | Silodosin |
| 69238-1420 | Silodosin | Silodosin |
| 69539-052 | SILODOSIN | SILODOSIN |
| 69539-053 | SILODOSIN | SILODOSIN |
| 72205-010 | SILODOSIN | SILODOSIN |
| 72205-009 | SILODOSIN | SILODOSIN |
| 62332-406 | Silodosin | Silodosin |
| 62332-405 | Silodosin | Silodosin |
| 72789-090 | SILODOSIN | SILODOSIN |
| 0023-6142 | RAPAFLO | silodosin |
| 0023-6147 | RAPAFLO | silodosin |
| 52544-151 | RAPAFLO | silodosin |
| 52544-152 | RAPAFLO | silodosin |